P
Peter R. Gibson
Researcher at Monash University
Publications - 553
Citations - 27949
Peter R. Gibson is an academic researcher from Monash University. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 79, co-authored 527 publications receiving 23585 citations. Previous affiliations of Peter R. Gibson include Austin Hospital & University of Adelaide.
Papers
More filters
Journal ArticleDOI
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
TL;DR: In a controlled, cross-over study of patients with IBS, a diet low in FODMAPs effectively reduced functional gastrointestinal symptoms and high-quality evidence supports its use as a first-line therapy.
Journal ArticleDOI
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
William J. Sandborn,Brian G. Feagan,Colleen Marano,Hongyan Zhang,Richard Strauss,Jewel Johanns,Omoniyi J. Adedokun,Cynthia Guzzo,Jean-Frederic Colombel,Jean-Frederic Colombel,Walter Reinisch,Peter R. Gibson,Judith Collins,Gunnar Järnerot,Toshifumi Hibi,Paul Rutgeerts +15 more
TL;DR: Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo.
Journal ArticleDOI
No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates
Jessica R Biesiekierski,S. L. Peters,Evan Newnham,Ourania Rosella,Jane G. Muir,Peter R. Gibson +5 more
TL;DR: In a placebo-controlled, cross-over rechallenge study, there is no evidence of specific or dose-dependent effects of gluten in patients with NCGS placed diets low in FODMAPs.
Journal ArticleDOI
Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial
Jessica R Biesiekierski,Evan Newnham,Peter M. Irving,Jacqueline Susanne Barrett,Melissa Haines,James D. Doecke,Susan Joy Shepherd,Jane G. Muir,Peter R. Gibson +8 more
TL;DR: “Non-celiac gluten intolerance” may exist, but no clues to the mechanism were elucidated and there were no differences in any end point in individuals with or without DQ2/DQ8.
Journal ArticleDOI
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
William J. Sandborn,Brian G. Feagan,Colleen Marano,Hongyan Zhang,Richard Strauss,Jewel Johanns,Omoniyi J. Adedokun,Cynthia Guzzo,Jean-Frederic Colombel,Jean-Frederic Colombel,Walter Reinisch,Peter R. Gibson,Judith Collins,Gunnar Järnerot,Paul Rutgeerts +14 more
TL;DR: Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg Golimumab had clinical remission and mucosal healing at weeks 30 and 54.